DiscoverMedicine via myPodThe Hematologist: DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma
The Hematologist: DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

The Hematologist: DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

Update: 2024-12-21
Share

Description

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.”

 


Episode: https://share.transistor.fm/s/fe725ea2


Podcast: https://ashpublications.org/thehematologist

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Hematologist: DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

The Hematologist: DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma